Noemi Reguart· @NReguart · X·· 15 hours agoScore70
Body · original
Impressive results from phase III DeLLphi-305 at #ESMO26 @sands_jacob: Adding tarlatamab to durvalumab maintenance in ES-SCLC 1-y OS nearly 80%!!!
🔹 OS: 21.1 vs 12.7 mo (HR 0.42)
🔹 PFS: 7.4 vs 1.9 mo (HR 0.34)
A standing ovation!” 👏👏👏👏A major step forward for SCLC! @NEJM
76 views · 2 likes · 0 reposts · 0 replies
Conference abstracts
LBA3matched by Presidential Symposium I
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: Noemi Reguart · x.com